Thymosin Alpha-1 and TB-500 sound like close relatives, and both trace back to the same calf thymus extract. In fact they are unrelated molecules. Thymosin Alpha-1 is a 28-residue acidic peptide studied in immune signaling. TB-500 is based on thymosin beta-4, a 43-residue protein whose best-known job is holding actin in reserve inside cells. This guide explains how they got similar names, compares them side by side and links to the full research overview for each.
All compounds discussed are sold for laboratory research use only. This page summarizes published research and is not guidance for human or veterinary use.
At a glance
| Thymosin Alpha-1 | TB-500 (thymosin beta-4) | |
|---|---|---|
| Family | Alpha thymosin; a fragment of prothymosin alpha | Beta thymosin |
| Size | 28 residues, 3108.3 g/mol | 43 residues, 4963 g/mol (full-length, as sold here) |
| Ends | N-terminally acetylated | N-terminally acetylated |
| Character | Strongly acidic, no cysteines | Largely unstructured in solution, one methionine |
| Best-documented biology | Immune signaling through toll-like receptors on dendritic cells | Binding monomeric actin in a 1:1 complex |
| Main research areas | Dendritic cell and T-cell biology, infection and tumor models, immune aging | Endothelial migration, cardiac and dermal injury models, tendon repair |
| Regulatory status | Not FDA approved; a synthetic form (thymalfasin) is approved in other countries | Not FDA approved; WADA S2 |
| Full overview | Thymosin Alpha-1 research | TB-500 research |
Why the names are so similar
In the 1960s and 1970s, Allan Goldstein’s laboratory prepared a calf thymus extract called thymosin fraction 5 and separated it into dozens of peptides. Each was named by where it ran on an isoelectric focusing gel: alpha peptides were acidic and beta peptides more neutral (Garaci, 2007). Thymosin Alpha-1 and thymosin beta-4 are both from that extract, which is why they share a name, but they have different sequences, sizes and functions.
Neither turned out to be thymus-specific. Thymosin Alpha-1 is the N-terminal region of prothymosin alpha, a nuclear protein found in many cell types (Dominari et al., 2020). Thymosin beta-4 is abundant in platelets, white blood cells and most other tissues.
Thymosin Alpha-1: an immune-signaling peptide
For decades Thymosin Alpha-1 was described by its effects on immune cells in culture, without a defined receptor. Work on mouse and human dendritic cells later linked it to toll-like receptor signaling, with reviews describing activity through TLR9 and TLR2 and downstream NF-kappaB activation (Goldstein et al., 2009). Its research covers T-cell maturation, infection and tumor models, and age-related changes in the thymus (Simonova et al., 2025).
Read the full Thymosin Alpha-1 research overview or view Thymosin Alpha-1.
TB-500: an actin-binding protein
Thymosin beta-4’s core biochemistry is well established: it binds monomeric actin and keeps a pool ready for rapid cytoskeleton remodeling. Safer and colleagues showed it was the same molecule as a platelet actin-sequestering factor (Safer et al., 1991). Because cell movement depends on actin turnover, later work found it increased directional migration of human endothelial cells (Malinda et al., 1997), and a mouse cardiac study linked it to the ILK-Akt pathway (Bock-Marquette et al., 2004). The name “TB-500” can also mean a short fragment of the actin-binding region; the TB-500 Rogue sells is the full 43-residue peptide.
Read the full TB-500 research overview or view TB-500.
Where their research overlaps
- Shared history: Both were characterized from thymosin fraction 5 by the same research program, and older studies of the mixture cannot be attributed to either peptide alone.
- Inflammation and injury models: Thymosin Alpha-1 is studied for immune-cell signaling in infection models, while thymosin beta-4 has been examined in rodent wound and injury models where inflammatory cell infiltration is one readout (Philp and Kleinman, 2010).
- No confirmed dedicated receptor: Neither has a structurally defined, high-affinity cell-surface receptor. Thymosin Alpha-1’s toll-like receptor model rests on functional studies, and how extracellular thymosin beta-4 acts is still not fully resolved.
How researchers choose between them
- Studying innate immune signaling, dendritic cells or T-cell biology: Thymosin Alpha-1 is the relevant tool.
- Studying actin dynamics, cell migration or vessel formation: TB-500 is the relevant tool.
- Studying the thymosin fraction 5 literature: testing the purified peptides separately is the way to tell which component accounts for an effect.
What the research does not show
Mechanistic data for both come from cell culture and animal models and do not establish effects or safety in humans. Older studies often used the thymosin fraction 5 mixture rather than a purified peptide. For TB-500, studies use different molecules under the same name, so results for a fragment cannot be assumed for the full-length protein. Clinical studies of thymalfasin involved a specific pharmaceutical product and do not transfer to research reagents. None of these findings describes the research material sold here.
Verify what you’re working with
With two similarly named peptides of different lengths, and “TB-500” used for more than one molecule, identity testing is what confirms what is in the vial. Every Rogue batch is tested by an independent, ISO 17025 accredited U.S. lab, and the QR code on each vial opens that batch’s report on the lab’s own website. See how to read a peptide COA or browse the COA Library.
View Thymosin Alpha-1 on Rogue Compounds
References
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:14-20. PMID 17567941
- Goldstein AL, et al. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608. PMID 19392576
- Dominari A, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PMID 33362999
- Simonova MA, et al. Aging and thymosin alpha-1. Int J Mol Sci. 2025;26(23):11470. PMID 41373628
- Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398
- Malinda KM, et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. PMID 9194528
- Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID 15565145
- Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. PMID 20536453
Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.
Compounds researchers often order together, 5% off as a set. Every vial ships with its batch COA.
TB-500 + THYMOSIN ALPHA-1From $114.00 
TB-500 + GHK-CuFrom $104.50 
THYMOSIN ALPHA-1 + GlutathioneFrom $114.00